Drug nanovectors (NVs) are expected to profoundly change therapeutic treatments in highly prevalent diseases such as rheumatoid arthritis. However, NV accumulation can be heterogeneous and a patient selection, based on imaging of NV fine localization, could improve treatment efficacy. The CAP-PHOTOAC project aims to develop clinically relevant NVs tagged with organic contrast agents for photoacoustic imaging (PAI) to elucidate intratissue distribution. PAI is an emerging imaging modality able to map (cm depth, ~0.1 mm resolution) optical absorption in vivo. Novel molecular absorbers will be developed to label the polymeric NVs. pH sensitive fluorophores will also be prepared and included in the NVs to study their cellular penetration. Labelled NVs will be characterized in terms of stability, biocompatibility, photophysical and photoacoustic properties. The kinetic of their intratissue and intracellular accumulation will be mapped in a mouse model by PAI and fluorescence imaging.
Madame Rachel Méallet-Renault (Institut des Sciences Moléculaires d'Orsay)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
LIB Laboratoire d'Imagerie Biomédicale
PPSM Photophysique et Photochimie Supramoléculaires et Macromoléculaires
ISMO Institut des Sciences Moléculaires d'Orsay
IGPS Institut Galien Paris Saclay
Help of the ANR 457,516 euros
Beginning and duration of the scientific project:
September 2021
- 48 Months
